Episode Details
Back to Episodes
Week in Review | GSK Kills Camlipixant: The P2X3 Cough Bet Just Went to Zero
Published 4 days, 19 hours ago
Description
GSK wrote off most of a $2 billion bet as camlipixantbecomes the third P2X3 antagonist to fail in chronic cough. Plus Lilly's $2.8B AtaiBeckley deal and July's IPO wave, Novartis Fabhalta's full approval in IgAN, Celcuity's Revtorpyk, Merck's oral PCSK9 pill and sac-TMT lung-cancerdata, the Jasper–Kira merger, and the Sanofi Sarclisa FDA decision ahead.
Visit us at thepharmacloseout.com.